$0.48
-0.03 (-6.02%)
Open$0.52
Previous Close$0.51
Day High$0.54
Day Low$0.46
52W High$5.33
52W Low$0.40
Volume—
Avg Volume1.11M
Market Cap24.48M
P/E Ratio—
EPS$-1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+3,937.8% upside
Current
$0.48
$0.48
Target
$19.24
$19.24
$16.83
$19.24 avg
$29.48
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 110.90M | 77.67M | 27.35M |
| Net Income | -34,460,458 | -21,720,297 | 6.20M |
| Profit Margin | -31.1% | -29.5% | 22.7% |
| EBITDA | -6,364,064 | -4,234,092 | 9.44M |
| Free Cash Flow | — | — | 4.10M |
| Rev Growth | +42.8% | +42.8% | -0.5% |
| Debt/Equity | 4.00 | 4.00 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |